Although it remains to be confirmed by in vivo preclinical studies, the ability of ATM-3507 to limit the in vitro growth and motility of DLBCL lines suggests that Tpm3.1/3.2 could be a therapeutic target for inhibiting DLBCL progression and dissemination. This evidence concerns the gene ATM and diffuse large B-cell lymphoma.